Abstract:
Described herein are compounds that are useful as ERK2 inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferate disorders such as cancer.
Abstract:
Described herein are compounds that are useful as protein kinase inhibitors of formula (I); or a pharmaceutically acceptable salt thereof, wherein Ring A, Z 1 , Z 2 , U, Q, R 1 , R 2 , and L are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.
Abstract:
Described herein are compounds that are useful as protein kinase inhibitors of formula (I) or a pharmaceutically acceptable salt thereof, wherein Ring B, Z , Z , U, p, Q, R , R , R , and R are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.
Abstract:
Described herein are compounds that are useful as protein kinase inhibitors having the formula: (I) where R , Q, and T are described inthe specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
Abstract:
The present invention provides a compound of formula I: (see formula I) or a pharmaceutically acceptable salt thereof. The compound or salt may be used to inhibit ERK1 or ERK2 protein kinase activity in a biological sample in vitro or treat or lessen the severity of melanoma, breast cancer, colon cancer, pancreatic cancer, kidney carcinoma, lung cancer, ovarian cancer or prostate cancer in a patient in need thereof.
Abstract:
Described herein are compounds that are useful as protein kinase inhibitors having the formula: (I) where R1-4, Q, and T are described in the specification. Th e compounds are useful for treating disease states in mammals that are alleviated by a prote in kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, an d cardiovascular disease.
Abstract:
Described herein are compounds that are useful as protein kinase inhibitors of formula I: or a pharmaceutically acceptable salt thereof, wherein Ring A, Z 1 , Z 2 , U, Q, R 1 , R 2 , and L are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.
Abstract:
The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.